WASHINGTON, Nov. 14, 2013 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA), a biopharmaceutical
company focused on the development and commercialization of
products for the treatment of central nervous system disorders,
today announced that NASDAQ halted trading of Vanda common stock
this morning.
The Peripheral and Central Nervous System Drugs Advisory
Committee to the U.S. Food and Drug Administration (FDA) meets
today to review Vanda's New Drug Application (NDA) for tasimelteon,
proposed trade name HETLIOZ™, for the treatment of
Non-24-Hour Disorder in the totally blind. The Advisory
Committee meeting is scheduled for 8:00 am
ET.
Vanda's HETLIOZ™ NDA is currently under Priority
Review by the FDA with an action target date under the Prescription
Drug User Fee Act (PDUFA-V) of January 31,
2014.
Investor Contact:
Chad
Rubin
Vice President
The Trout Group
(646) 378-2947
crubin@troutgroup.com
Media Contact:
Laney Landsman
Assistant Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com
SOURCE Vanda Pharmaceuticals Inc.